Currently, clinical trials using TLR3 agonists in combination with GM-CSF (ClinicalTrials.gov Identifier: NCT02149225) or peptide vaccine (ClinicalTrials.gov Identifier: NCT01920191) for treatment of GBM are being initiated. Here, TLR3 is linked to glioblastoma.